Founder & CEO, GraftWorx, Inc.
David Kuraguntla was preparing to begin a surgical residency when he was confronted with the need for the GraftWorx device. While researching a possible solution, he invented the GraftWorx technology and currently leads the company as Co-founder and CEO. GraftWorx is developing a series of “smart” devices to treat patients who need dialysis or suffer from peripheral arterial disease (PAD). Their sensor-enabled wearables and stents can connect to smartphones and alert surgeons before a problem becomes clinically evident. These alerts then benefit the patient, payer, and provider by avoiding costly, debilitating outcomes. Leveraging their technology and proprietary cloud software to change lives, GraftWorx is turning the Internet of Things into the Internet of the Body.
David attended West Virginia School of Osteopathic Medicine on a Health Professions Scholarship from the United States Air Force. In addition, he worked at the National Institute on Drug Abuse (NIDA), where he developed a novel live-cell confocal microscopy technique to study the dopamine transporter function, kinase pathways, and drug interactions. As a recipient of a National Science Foundation grant, David performed physical organic synthesis on propellane and its derivatives.